Samantha focuses her practice on securities transactions, public offerings, corporate governance, and general corporate matters.
While attending law school, Samantha served as a legal extern in the Boston office of an international mutual life insurance company and an in-house legal intern at a California-based brewery. In law school, Samantha served as a member of the Review of Banking and Financial Law.
Before attending law school, Samantha had a summer legal internship with a law firm in California.
viewpoints
Recent SEC Rules and Guidance Impose New Obligations on SPACs and Reverse Mergers
May 15, 2024 | Alert | By Anne Bruno, Daniel T. Kajunski, Samantha Silver
Read about how the SEC’s final rules relating to special purpose acquisition companies (SPACs) and other shell companies, which take effect on July 1, 2024, and the agency’s recent guidance on reverse mergers are likely to impact SPAC-related transactions and alternative capital raising transactions.
News & Press
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Publications
- Author, Federal Reserve Corporate Governance Proposal and Its Potential Effects, Review of Banking and Financial Law (2017)
Read less
Recent Insights
Recent SEC Rules and Guidance Impose New Obligations on SPACs and Reverse Mergers
May 15, 2024| Alert|
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
